Objective: To evaluate the clinical efficacy of Conbercept on macular edema secondary to branch retinal vein occlusion and to explore the relevant influencing factors. Method: The clinical data of 94 patients (94 eyes) with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in the Second Affiliated Hospital of Guizhou Medical University from January 2015 to September 2019 were collected. All patients received 3+PRN intravitreal injection of Conbercept. The best corrected visual acuity (BCVA), central macular thickness (CMT), ellipsoid zone and external membrane integrity were observed before treatment and 1, 3, 6 and 12 months after treatment. Result：The constituent characteristics of different nationalities in this study are 38.30% (36 / 94) of Han nationality, 34.04% (32 / 94) of Miao nationality and 27.66% (26 / 94) of Dong nationality.The clinical baseline data (age, gender, preoperative BCVA, and CMT) of ME secondary to BRVO in different nationalities were not statistically significant. There was no significant difference in BCVA and CMT between Han, Miao and Dong nationalities at 1, 3, 6 and 12 months after operation. Patients’ BCVA of different nationalities at 1, 3, 6 and 12 months after operation was significantly higher than that before treatment (P < 0.05). Patients’ CMT of different nationalities decreased significantly after 1, 3, 6 and 12 months (P < 0.05). In the multiple regression analysis of this study, baseline CMT was not related to baseline BCVA (P > 0.05). Age, course of disease and integrity of the ellipsoid zone were related to baseline BCVA (P < 0.05). Baseline BCVA and baseline external membrane integrity were related to BCVA (P < 0.05). Conclusion：In the treatment of ME secondary to BRVO, Conbercept shows time stability and broad-spectrum demographic characteristics, and it can be widely used in ethnic minority areas in Southeast Guizhou.

Objective: To evaluate the clinical efficacy of Conbercept on macular edema secondary to branch retinal vein occlusion and to explore the relevant influencing factors. Method: The clinical data of 94 patients (94 eyes) with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in the Second Affiliated Hospital of Guizhou Medical University from January 2015 to September 2019 were collected. All patients received intravitreal injection of Conbercept. The best corrected visual acuity (BCVA), central macular thickness (CMT), ellipsoid zone and external membrane integrity were observed before treatment and 1, 3, 6 and 12 months after treatment. Result: The constituent characteristics of different nationalities in this study are 38.30% (36 / 94) of Han nationality, 34.04% (32 / 94) of Miao nationality and 27.66% (26 / 94) of Dong nationality. The clinical baseline data (age, gender, preoperative BCVA, and CMT) of ME secondary to BRVO in different nationalities were not statistically significant. There was no significant difference in BCVA and CMT between Han, Miao and Dong nationalities at 1, 3, 6 and 12 months after operation. BCVA in patients of different nationalities at 1, 3, 6 and 12 months after operation was significantly higher than that before treatment (P < 0.05). CMT in patients of different nationalities decreased significantly after 1, 3, 6 and 12 months (P < 0.05). In the multiple regression analysis of this study, baseline CMT was not related to baseline BCVA (P > 0.05). Age, course of disease and ellipsoid band integrity were related to baseline BCVA (P< 0.05). Baseline BCVA and baseline external membrane integrity were related to BCVA (P < 0.05). Conclusion: In the treatment of ME secondary to BRVO, Conbercept shows time stability and broad-spectrum demographic characteristics, and it can be widely used in ethnic minority areas in Southeast Guizhou.